Original Research

Published on 12 Apr 2022

Airway Microbiota in Patients With Synchronous Multiple Primary Lung Cancer: The Bacterial Topography of the Respiratory Tract

in Thoracic Oncology

Kai Qian
Yi Deng
William S. Krimsky
Yong-Geng Feng
Jun Peng
Yong-Hang Tai
Hao Peng
Li-Hong Jiang

Frontiers in Oncology

doi 10.3389/fonc.2022.811279

2,251 views
3 citations

Review

Published on 12 Apr 2022

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases

in Thoracic Oncology

Thomas Pierret
Niccolò Giaj-Levra
Anne-Claire Toffart
Filippo Alongi
Denis Moro-Sibilot
Elisa Gobbini

Frontiers in Oncology

doi 10.3389/fonc.2022.787080

5,395 views
4 citations

Review

Published on 08 Apr 2022

Thymic Carcinoma: A Review

in Thoracic Oncology

Doaa Alqaidy
Cesar A. Moran

Frontiers in Oncology

doi 10.3389/fonc.2022.808019

11,405 views
4 citations

Review

Published on 07 Apr 2022

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance

in Thoracic Oncology

Emna Mahfoudhi
Charles Ricordel
Gwendoline Lecuyer
Cécile Mouric
Hervé Lena
Rémy Pedeux

Frontiers in Oncology

doi 10.3389/fonc.2022.853501

8,030 views
3 citations

Review

Published on 06 Apr 2022

Targeting ALK Rearrangements in NSCLC: Current State of the Art

in Thoracic Oncology

Ling Peng
Liping Zhu
Yilan Sun
Justin Stebbing
Giovanni Selvaggi
Yongchang Zhang
Zhentao Yu

Frontiers in Oncology

doi 10.3389/fonc.2022.863461

15,936 views
32 citations

Review

Published on 01 Apr 2022

Molecular Mechanisms Involving the Sonic Hedgehog Pathway in Lung Cancer Therapy: Recent Advances

in Thoracic Oncology

Chao Ma
Kang Hu
Irfan Ullah
Qing-Kang Zheng
Nan Zhang
Zhi-Gang Sun

Frontiers in Oncology

doi 10.3389/fonc.2022.729088

3,600 views
11 citations

Original Research

Published on 31 Mar 2022

A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial

in Thoracic Oncology

Carolyn J. Presley
Mostafa R. Mohamed
Eva Culakova
Marie Flannery
Pooja H. Vibhakar
Rebecca Hoyd
Arya Amini
Noam VanderWalde
Melisa L. Wong
Yukari Tsubata

Frontiers in Oncology

doi 10.3389/fonc.2022.835582

2,886 views
9 citations

Review

Published on 31 Mar 2022

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective

in Thoracic Oncology

Ningning Yan
Sanxing Guo
Huixian Zhang
Ziheng Zhang
Shujing Shen
Xingya Li

Frontiers in Oncology

doi 10.3389/fonc.2022.863043

23,135 views
37 citations

Case Report

Published on 31 Mar 2022

Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report

in Thoracic Oncology

Shilan Liu
Xiao Liu
Ting Wang
Chunhua Zeng
Baichen Ren
Xiaodan Yu
Min Xu
Wenjuan Li
Zhihui Qiao
Chuanyun You

Frontiers in Oncology

doi 10.3389/fonc.2022.789941

1,562 views

Review

Published on 29 Mar 2022

HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies

in Thoracic Oncology

Xin Yu
Xianxiu Ji
Chunxia Su

Frontiers in Oncology

doi 10.3389/fonc.2022.860313

17,135 views
19 citations

Case Report

Published on 29 Mar 2022

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series

in Thoracic Oncology

Shao Feng
Zhang Qiang
Cheng Wanwan
Zeng Zhaozhun
Xie Yuewu
Fang Shencun

Frontiers in Oncology

doi 10.3389/fonc.2022.872225

2,828 views
4 citations

Original Research

Published on 28 Mar 2022

Identification of a Prognostic Signature Composed of GPI, IL22RA1, CCT6A and SPOCK1 for Lung Adenocarcinoma Based on Bioinformatic Analysis of lncRNA-Mediated ceRNA Network and Sample Validation

in Thoracic Oncology

Wenjun Tang
Qiaonan Lu
Jianling Zhu
Xiaowei Zheng
Na Fang
Shaoping Ji
Feng Lu

Frontiers in Oncology

doi 10.3389/fonc.2022.844691

2,942 views
3 citations

Original Research

Published on 28 Mar 2022

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

in Thoracic Oncology

Brendan Knapp
Laura Mezquita
Siddhartha Devarakonda
Mihaela Aldea
Saiama N. Waqar
Kym Pepin
Jeffrey P. Ward
Angela Botticella
Karen Howarth
Charlene Knape

Frontiers in Oncology

doi 10.3389/fonc.2022.856132

3,916 views
3 citations

Original Research

Published on 25 Mar 2022

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1

in Thoracic Oncology

Vamsidhar Velcheti
Xiaohan Hu
Lingfeng Yang
M. Catherine Pietanza
Thomas Burke

Frontiers in Oncology

doi 10.3389/fonc.2022.834761

8,594 views
20 citations

Original Research

Published on 21 Mar 2022

EGFR Q787Q Polymorphism Is a Germline Variant and a Prognostic Factor for Lung Cancer Treated With TKIs

in Thoracic Oncology

Wen-Jui Wu
Sheng-Hsiung Yang
Hsin-Pei Chung
Chia-Te Yen
Yen-Ting Chen
Wei-Chin Chang
Jian Su
Hsuan-Yu Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.816801

2,126 views
2 citations

Original Research

Published on 18 Mar 2022

Based on SEER Database: Population Distribution, Survival Analysis, and Prognostic Factors of Organ Metastasis of Lung Large Cell Neuroendocrine Carcinoma

in Thoracic Oncology

Chang-fu Liu
Yu-jian Tao

Frontiers in Oncology

doi 10.3389/fonc.2022.810170

3,932 views
3 citations

Navigation group

Articles

Airway Microbiota in Patients With Synchronous Multiple Primary Lung Cancer: The Bacterial Topography of the Respiratory Tract

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases

Thymic Carcinoma: A Review

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance

Targeting ALK Rearrangements in NSCLC: Current State of the Art

Molecular Mechanisms Involving the Sonic Hedgehog Pathway in Lung Cancer Therapy: Recent Advances

A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective

Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report

HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series

Identification of a Prognostic Signature Composed of GPI, IL22RA1, CCT6A and SPOCK1 for Lung Adenocarcinoma Based on Bioinformatic Analysis of lncRNA-Mediated ceRNA Network and Sample Validation

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1

EGFR Q787Q Polymorphism Is a Germline Variant and a Prognostic Factor for Lung Cancer Treated With TKIs

Based on SEER Database: Population Distribution, Survival Analysis, and Prognostic Factors of Organ Metastasis of Lung Large Cell Neuroendocrine Carcinoma